Transdermal Patch Drug Deliver Market Opportunity To Surpass USD 20 Billion By 2028 As Per Kuick Research Report Findings.
Transdermal Patch Drug Deliver Market Opportunity To Surpass USD 20 Billion By 2028 As Per Kuick Research Report Findings
Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
- Research Methodology
- Global & Regional Transdermal Path Market Outlook
- Global Transdermal Patch Market Opportunity > USD 20 Billion
- Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
- Comprehensive Insight On 60 Transdermal Patch Available Commercially
- Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
- Transdermal Patch Dosage & Price Availability By Indication
- Competitive Landscape
Download Report:
https://www.kuickresearch.com/report-global-transdermal-patch-market
Oral administration of drugs is one of the oldest methods known to mankind but it is not suitable for all patients. For several decades, investigators are trying to develop drugs that could be administrated through different routes with high efficacy. Amongst the newer methodologies for administration of medicines is the use of transdermal approaches, including gels and patches for the treatment of many of the more common ailments. The creation of transdermal delivery systems has been one of the most important innovations, offering a number of advantages over the oral route. Transdermal patches comprise a method of delivering medication through the skin in a non-invasive manner.
The transdermal patch is modulated to contain the medication prescribed to the patient and is designed in such a way that the medication permeates the skin in a controlled fashion thus attaining more steady levels of the drug in the body. Currently, transdermal patches have gained the maximum interest owing to its advantages over traditional pill, powder, or liquid medication delivery methods. The major benefit of using patches is the method’s direct-to-bloodstream delivery while bypassing the liver’s metabolic activity. Another, by using using patches is that medication is supplied gradually and constantly, rather than in a large, single dose. Additionally, patches are painless, eliminating the need for injections that can cause a patient irritation and discomfort. Patches are simply placed on the skin, worn for a prescribed period of time, and removed, thus making them more convenient.
Till date, a cocktail of transdermal patches including fentanyl transdermal patch, nicotine transdermal patch, buprenorphine transdermal patch, clonidine transdermal patch, oxybutynin transdermal patch and others. The entrance of these have demonstrated huge adoption rate among patients across wide range of therapeutic indications including migraine, Parkinson disorder, Alzheimer, stroke, osteoporosis, dermatology related issue, restless leg syndrome, amongst others.
Raising unmet medical demand for has created a burgeoning pressure on pharmaceutical companies to invest more on transdermal patches. They are non-invasive, doesn’t bother patients and easy application is causing increased number of patients to opt for transdermal patches. With time, new disease indications are being treated with the help of transdermal patches. For instance, researchers in ACS Nano have developed a microneedle patch which delivers a COVID-19 DNA vaccine into the skin, causing strong immune responses in cells and mice. More importantly, these patches can be stored for over 30 days at room temperature.
The global transdermal patch pharmaceutical industry is rapidly evolving and experiencing fierce competition. Mergers and acquisitions form one of the key sustainable strategies undertaken by market players. Recently in 2021, PharmaTher Holdings entered into research collaboration with Revive Therapeutics to evaluate the delivery of psilocybin with PharmaTher’s proprietary microneedle patch technology for neuropsychiatric disorders. PharmaTher is currently conducting IND labeling research studies with MicroDose-MN, a patent pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022. The company is also conducting research studies with its MicroDose-MN and MacroDose-MN patch as a next generation delivery system for psychedelics with ketamine 3,4- methylenedioxy-methamphetamine (MDMA), lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT). Also, the company has decided to expand research to include ibogaine and mescaline.
As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028. The global market is driven by rise in patient population experiencing chronic pain, cancer pain, increased demand for OTC patches, and rising availability of generic patches. The introduction in the modern technologies contributes to the growth of transdermal patches market during the forecast period. These advancements aid in increasing the number of drugs being delivered transdermally including small molecule hydrophobic drugs, hydrophilic drugs, and macromolecules.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com